Skip to main content
TipRanks
Go Ultimate75% OFF

American Vanguard (AVD) AI Stock Analysis

302 Followers
AVD

American Vanguard

(NYSE:AVD)

Select Model
Rating:42Neutral
Price Target:$0.84â–¼(-3.65% Downside)
Action:reiterated
Date:11/12/26

The score is held down primarily by weak financial performance (net losses and negative operating/free cash flow) and clearly bearish technical signals (price below key moving averages with negative MACD). Valuation is difficult to justify positively due to a negative P/E, while the latest earnings call provides only partial offset: Q4 improvement initiatives and liquidity progress were tempered by lowered full-year guidance and leverage near covenant limits.

Positive Factors
Portfolio expansionThe Syngenta portfolio acquisition and Sipcam distribution agreement broaden American Vanguard’s product reach and revenue base. Their expected contribution over the next 12 months provides a tangible growth avenue and can strengthen commercial scale if execution and customer adoption continue.
Negative Factors
Persistent unprofitabilityDeclining TTM revenue and a sizable net loss show that American Vanguard is not currently converting its product portfolio into sustainable earnings. Continued margin pressure limits internal funding capacity and makes recovery dependent on successful cost actions and improved operating performance.

American Vanguard (AVD) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%AVD-81.48%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$25.89M
Dividend Yield
―
Average Volume (3M)
423.16K
Price to Earnings (P/E)
-0.4
Beta (1Y)
1.54
Revenue Growth
-5.79%
EPS Growth
46.69%
Country
US
Employees
739
Sector
Basic Materials
Sector Strength
61
Industry
Agricultural Inputs

American Vanguard Business Overview & Revenue Model

Company Description

American Vanguard Corporation, through its various subsidiaries, develops, manufactures, and markets a diverse portfolio of specialized chemicals for agricultural, commercial, and consumer applications across the United States and internationally. Th...

How the Company Makes Money

American Vanguard primarily makes money by selling pest-control and crop protection chemicals and related solutions, with revenue recognized from product shipments to customers through multiple go-to-market channels. Key revenue streams include: (1)...

American Vanguard Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:7.48%|Next Earnings Date:Mar 18, 2027
Earnings Call SentimentNeutral

The call presented a mixed outlook. Management highlighted improved customer prepayments, liquidity, cost actions, new product and portfolio initiatives, and expectations for stronger fourth-quarter results. However, third-quarter revenue and EBITDA declined, gross margins contracted, international markets remained weak, transportation costs increased sharply, leverage stayed close to the covenant maximum, and full-year revenue and adjusted EBITDA guidance were reduced. The positive initiatives and fourth-quarter expectations were balanced by significant current operating and market challenges.

Positive Updates

Customer Prepayments and Liquidity Improved
Customer prepayments increased 44% over the prior-year quarter. Cash ended the quarter at $84 million, up $40 million sequentially, while net debt was approximately $183.8 million, down $40 million sequentially. The company also reduced inventory by $4.9 million year-over-year through tighter production planning and improved sales, inventory, and operating planning processes.

Negative Updates

Third-Quarter Revenue and EBITDA Decline
Third-quarter net sales were $108 million, down 9% from $119 million in the third quarter of 2025. Adjusted EBITDA was approximately breakeven, down $8.3 million year-over-year.

Company Guidance

American Vanguard now expects full year 2026 revenue to be in the range of $500 million to $530 million and adjusted EBITDA to come in the $36 million to $40 million range; for the fourth quarter, it projects net sales of approximately $166 million, up 10% versus the year ago period, and adjusted EBITDA of $21 million, up roughly 25% versus last year's fourth quarter, while anticipating fourth quarter prepayment and early pay collections of $45 million and net working capital to be a positive contributor to liquidity. The Syngenta portfolio and Sipcam Agro distribution agreement are projected to add a total of $15 million to $20 million in annualized revenue over the next 12 months, the company’s goal remains 50 new product launches, driving $100 million in annualized revenue by 2030, and it expects to reach an annualized run rate of more than $600 million in sales by the back half of 2028, approximately 20% above our 2025 level.

American Vanguard Financial Statement Overview

Summary

Operating results and cash generation are the key weaknesses: TTM revenue is down (-2.1%) with a sizable net loss (~-12% net margin) and negative operating/free cash flow. The balance sheet is more supportive (low TTM debt-to-equity ~0.13x), but recent leverage history was elevated and returns are negative (TTM ROE ~-27.8%), keeping the overall financial profile pressured despite some improvement from 2024.

Income Statement

28Negative

Balance Sheet

54Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue499.39M515.11M547.31M579.37M609.62M557.68M
Gross Profit141.99M147.56M120.32M179.16M241.35M170.72M
EBITDA-11.33M-11.79M-9.66M44.72M62.22M57.00M
Net Income-59.89M-49.88M-126.34M7.52M27.40M18.59M
Balance Sheet
Total Assets663.41M596.54M636.72M767.55M726.31M694.16M
Cash, Cash Equivalents and Short-Term Investments83.91M12.43M12.51M11.42M20.33M16.29M
Total Debt284.57M191.39M167.81M162.09M76.25M78.08M
Total Liabilities500.29M404.14M403.61M397.54M356.33M321.42M
Stockholders Equity163.12M192.40M233.11M370.01M369.98M372.74M
Cash Flow
Free Cash Flow-12.62M-25.27M-3.77M-70.81M42.55M76.32M
Operating Cash Flow-6.39M-21.19M3.92M-58.75M57.10M86.36M
Investing Cash Flow-11.38M-3.61M-6.62M-17.02M-14.47M-20.04M
Financing Cash Flow85.31M23.70M4.54M66.74M-38.26M-65.87M

American Vanguard Technical Analysis

Technical Analysis SentimentNegative
Last Price0.88

Price Trends

50DMA1.52Negative
100DMA2.00Negative
200DMA2.68Negative

Market Momentum

MACD-0.18Negative
RSI27.36Positive
STOCH26.46Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVD, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.52, and below the 200-day MA of 2.68, indicating a bearish trend. The MACD of -0.18 indicates Negative momentum. The RSI at 27.36 is Positive, neither overbought nor oversold. The STOCH value of 26.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVD.

American Vanguard Risk Analysis

American Vanguard disclosed 28 risk factors in its most recent earnings report. American Vanguard reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.The development of Agentic AI tools may overtake the efficacy of available cybersecurity defense tools and, as such, could put the Company's computing systems at risk.Q2, 2026
2.The Company's primary synthesis factories are dependent upon the continued provision of shared services from competitors.Q2, 2026
3.The war between the US and Iran coupled with instability among other nations within the Middle East may have an adverse effect upon the agricultural economy in general and the Company's financial performance in particular.Q2, 2026

American Vanguard Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

AVD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IPIIPI65Neutral$439.82M17.914.81%―5.04%―
UANUAN65Neutral$1.19B11.1535.58%12.85%7.31%-16.36%
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%
BHSTBHST43Neutral$34.12M-2.74-55.88%―4.76%23.09%
AVDAVD42Neutral$25.89M-0.42-32.98%―-5.79%46.69%
BIOXBIOX38Underperform$13.40M-0.06-216.09%―-26.10%14.85%

* Basic Materials Sector Average

Performance Comparison

-50%0%50%AVDUANIPIBHSTBIOXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AVD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AVDAmerican Vanguard Corporation0.88-3.92-81.75%
UANCVR Partners LP112.6023.1025.80%
IPIIntrepid Potash Inc32.917.9531.85%
BHSTBioharvest Sciences, Inc.1.50-5.16-77.40%
BIOXBioceres Crop Solutions0.21-1.33-86.41%

American Vanguard Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions

American Vanguard Reports Third-Quarter 2026 Financial Results

Negative
Nov 10, 2026

On November 9, 2026, American Vanguard reported unaudited third-quarter and nine-month results ended September 30, 2026. Third-quarter net sales fell to $108 million from $119 million, gross margin to 24% from 29%, operating loss widened to $8.0 mill...

Business Operations and StrategyExecutive/Board Changes

American Vanguard appoints new chief financial officer

Positive
Oct 1, 2026

On October 1, 2026, American Vanguard’s board completed a planned leadership transition in its finance organization, appointing 43-year-old Matthew Horwath as Chief Financial Officer and moving long-serving CFO David Johnson to the role of Chief Acco...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026